ArticleFuture medicinal chemistry2025
Exploring Schiff base bromhexine derivatives: study on synthesis, characterization, biological assays, molecular docking.
Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSchiff bases, owing to their versatile pharmacological and industrial applications, have attracted significant attention in drug design. MATERIAL AND
methodsThe newly synthesized Schiff Base derivatives of bromhexine were characterized using spectral techniques, including Infrared (IR), Nuclear Magnetic Resonance (1 H NMR, 13C NMR) analyses. Pharmacokinetic studies via SwissADME web server. Antiviral screening using the hemagglutination inhibition assay identified BM9 as the most potent compound (IC50 = 3.01 ± 1.70). Antioxidant activity was assessed using the DPPH method. RESULTS AND
conclusionMolecular docking studies against α-amylase and α-glucosidase revealed strong inhibition scores, with BM6 and BM7 emerging as the most promising candidates. This study concludes that derivatives could serve as lead compounds in the development of novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.